What’s ahead with the new Trump administration?

January 19, 2017 Christoph Graener

It’s no secret that the life sciences industry has had some challenging moments with lawmakers in recent years. And despite efforts by the White House, Congress, FDA, and other regulatory agencies, in most cases the law continues to lag behind the industry’s pace of innovation. So, how will the Trump Administration address the industry’s challenges?

Moderator: Senator Norm Coleman – Hogan Lovells

  • Jane Axelrad – Axelrad Solutions LLC; Formerly FDA
  • Julie Gerberding – Merck & Co., Inc.
  • Greg Simon – White House Cancer Moonshot Task Force

Previous Article
Unmet needs, uncommon commitment: The shift toward investment in rare diseases
Unmet needs, uncommon commitment: The shift toward investment in rare diseases

Join biotech leaders, emerging innovators, investors and patient advocacy group reps for a candid, interact...

Next Article
State of the Digital Medicine Industry

Tools that will usher in a new age of healthcare are changing the game by creating more effective R&D proce...